background image for GxP Lifeline
GxP Lifeline
  • newsletter subscription

    "Death by Risk-Based Approach: The Practical Guide to the ISO 13485:2016 Practical Guide, Part 3"

    This is the third post in the series, “The Practical Guide to the ISO 13485:2016 Practical Guide” for medical devices. This post explores examples and application provided within Practical Guide for the implementation of a “risk-based approach.”

    Full story
  • MasterControl Logo

    What Improv Comedy Can Teach Us About Communication in Clinical Trials

    A look at how some of the insights behind improv comedy training can help clinical trial teams develop and improve communication and problem-solving skills. It's no laughing matter.

    Full story
  • MasterControl Logo

    What, No Installation Records?

    Christopher J. Devine delves into the topic of medical device installation recordkeeping, and why proper documentation of this process is essential to successfully installing medtech and avoiding warning letters and other mishaps.

    Full story
  • digital-business-documents-132

    February Tip: Managing Updates to Regulatory Documentation

    Tip: When the change occurs, review the current regulatory submission(s) and note where updates are needed. Even better, create a working or dynamic version of an updated submission.

    Full story
  • smart-document-contract-132

    New European Med Device Regulation: 2020 Looms Large for Medtech Firms

    In 2020, the United States will hold a presidential election. Tokyo will host the Summer Olympics. For the medtech industry, the European Union’s Medical Device Regulation (MDR) will take effect. Politicians and athletes have been gearing up for 2020 and so should medical device firms.

    Full story
  • MasterControl Logo

    3 Valuable Takeaways from the 2018 TMF U.S. Summit

    Clinical professionals from around the U.S. gathered Jan. 16-18 at the TMF U.S. Summit 2018 in Orlando, Fla., to discuss current clinical study trends and some of the pressing issues relating to trial master file (TMF) management. Three underlying themes were prevalent throughout the 7th annual event.

    Full story
  • 2017-bl-thumb-mobile-device-cybersecurity

    Cybersecurity in a Mobile World

    Mobile device technology appears to be taking off. Lately, it seems there are more non-phone-call uses for mobile devices than there are lightbulb jokes. The healthcare industry is becoming particularly mobile device heavy. However, in terms of cybersecurity, mobile medical device technology is causing headaches for healthcare organizations.

    Full story
  • 2022-bl-gxp-lifeline-quality-4.0-oqsie_1200x628

    February Tip: Continuous Employee Training Reduces Deviations and Nonconformances

    This blog post is part of an ongoing series to provide the latest tips from experts in the field to help readers keep up with changes in the quality and regulatory industry .

    Full story
  • MasterControl Logo

    Are Clinical Research Sites a Dying Paradigm?

    A recent analysis by the Manhattan Institute determined that Phase III clinical trials account for 90% or more of the cost of developing an approved drug from laboratory to pharmacy. [1] Given that reliable estimates put the cost of developing, and gaining marketing approval for a new drug, at well over a billion dollars,[2] it’s clear that human trials are pivotal to the pharmaceutical industry scrambling to find ways to reduce costs and speed timelines, while maintaining the quality and efficacy of the research.

    Full story
  • 2020-bl-thumb-align-quality-across-ecosystem_132x132

    What Do Changes to Australia’s PIC/S Guide to GMP Mean for Pharma Down Under?

    It’s said that change is never easy. But in the pharmaceutical industry, flexibility, and adaptability are part and parcel of successfully delivering the safest, highest quality products to a global market.

    Full story
  • MasterControl Logo

    January Tip: Strategies for New Regulatory Managers

    A good place to start is to identify the key stakeholders and decision makers in each department. This exercise will show you how close what is on paper is aligned to what is done in practice. Finding out “who is who” in each department will come with an explanation of their activities… pay attention to the overall scheme and coordination that takes and the various approaches, tactics, and means each department uses to accomplish their tasks. You will need this understanding to be effective as a regulatory leader.

    Full story
  • newsletter subscription

    Data Integrity: A Return to Basics

    Since the U.K.’s Medical and Healthcare product Regulatory Agency (MHRA) (1) and the U.S.’s Food and Drug Administration (FDA) (2), published on this subject in 2015 and 2016, respectively, data integrity continues to gain importance as an issue. Some workshop participants wondered if this is simply a new trending topic that will quickly fade. I firmly believe that it is not.

    Full story
  • MasterControl Logo

    January Tip: How to Choose and Use External Consultants

    External consulting firms can be used to provide expert help for many of the standard responsibilities that the quality department is tasked with. These external organizations are ready to provide you with the necessary documents to get on your approved supplier list, and can jump into work at various stages. Look for organizations that have specialized experience in the area(s) you are looking for and they can quickly and effectively help.

    Full story
  • 2018-bl-thumb-right-eqms-homeopath

    The Right EQMS for the Homeopathy Crackdown

    For nutraceutical companies, recent headlines promising an FDA crackdown on homeopathic products were probably a bit unsettling. Traditionally the FDA hasn't been involved with homeopathy, but this new guidance means that companies will have to become compliant with these six risk-based categories.

    Full story
  • 2018-bl-clear-as-mud-page-image

    Risk-Based Approach as Clear as Mud

    This is the second post in the series “The Practical Guide to the ISO 13485:2016 Practical Guide.” If you missed the first installment, catch up by reading it here. This post explores how the Practical Guide defines “risk-based approach,” varying terminology, and which systems require it.

    Full story
  • 2018-bl-thumb-ensuring-quality-med-device

    Ensuring Quality In Medical Device Trials

    Manufacturers have used a quality systems approach to ensure consistency within their processes for years, but the FDA is now encouraging clinical researchers to take a similar approach to medical device trials.

    Full story
  • paper-to-digital-documents-132

    4 Ways an EQMS Can Help You Improve Supplier Visibility

    Leveraging a centralized electronic quality management system (EQMS) can help medical device manufacturers bring together all quality data, leading to greater visibility and solutions to at least four key quality challenges across the extended supply chain, according to MasterControl Senior Product Manager Terrance Holbrook.

    Full story
  • newsletter subscription

    Software as a Medical Device: What Does It Mean and Why Should I Care?

    A little over a year ago, the U.S. Federal Drug Administration (FDA) released its draft guidance (1) regarding a newer, skyrocketing segment of the medical device industry—that of Software as a Medical Device (SaMD). The guidance means to address the emergence of thousands of stand-alone, health-oriented software apps that fall into a gray area in terms of regulation. Obviously, SaMDs aren’t traditional medical devices, but neither are they Pokémon Go.

    Full story
  • 2017-bl-thumb-santas-kitchen

    How Santa’s Kitchen Prepares for an FDA Inspection

    Before Santa can fill the stockings of good children from across the world, he and his elves must be inspected and/or audited by certified auditing bodies and similar organizations from around the world. Why? Because Santa must prove that the sweet treats he manufactures measure up to high quality standards for all children everywhere.

    Full story
  • 2017-bl-thumb-magnifying-glass

    FDA Draft Guidance on Electronic Records and Signatures: The Next Chapter

    Just about everyone in the drug development industry has cited 21 CFR Part 11 at one time or another. Fondly referred to as “Part 11,” the August 1997 regulation was last referenced by the FDA in 2003 with the release of a Guidance for Industry - Part 11, Electronic Records; Electronic Signatures — Scope and Application.1 Since then, the centralized research team has significantly changed from only a few stakeholders into a system of many globally distributed contributors. The industry’s documentation has transitioned from paper files to dynamic, integrated systems supporting digital records spanning the bedside to the research clinic. The delivery of healthcare has evolved from the confines of brick and mortar to cloud-based platforms that could only be dreamed of a few years ago.

    Full story
[ { "key": "fid#1", "value": ["GxP Lifeline Blog"] } ]